Physician profile
Shane E Wing
NPI 1730718818
$7,679.86
in general payments reported to CMS, 2019-2025
50 companies · $3,405 in 2025
The $3,405 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.12 · 2023: $864 · 2024: $3,398 · 2025: $3,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,567 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,566.75 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $585.07 | 2023-2025 | Ultomiris |
| Genzyme Corporation | $455.05 | 2023-2025 | |
| Eisai INC. | $415.66 | 2023-2025 | |
| Amgen INC. | $380.23 | 2023-2024 | Kyprolis, Lumakras, Xgeva |
| Abbvie INC. | $362.59 | 2024-2025 | |
| Janssen Biotech, INC. | $353.39 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Sobi, INC | $327.94 | 2023-2025 | |
| Pfizer INC. | $327.28 | 2024-2025 | |
| Pharmaessentia USA Corporation | $319.80 | 2023-2025 | Besremi |
| Merck Sharp & Dohme LLC | $277.31 | 2024-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $261.66 | 2024-2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $234.46 | 2022-2025 | Imfinzi, Tagrisso |
| Aveo Pharmaceuticals, INC. | $234.00 | 2024-2025 | |
| Caris Mpi, INC. | $223.29 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $207.68 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $199.33 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Tersera Therapeutics LLC | $170.38 | 2023-2025 | Xermelo, Quzyttir, Zoladex |
| Novartis Pharmaceuticals Corporation | $164.17 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $160.70 | 2024-2025 | Libtayo |
| Stemline Therapeutics INC. | $155.36 | 2024-2025 | Orserdu, Elzonris |
| Beigene USA, INC. | $151.49 | 2023-2024 | Brukinsa |
| Glaxosmithkline, LLC. | $131.13 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $128.54 | 2023-2025 | Jakafi, Monjuvi |
| Genentech USA, INC. | $120.40 | 2023-2025 | Phesgo, Tecentriq, Kadcyla |
| Exelixis INC. | $117.50 | 2024-2025 | Cabometyx |
| Beone Medicines USA, INC. | $111.65 | 2025 | Tevimbra, Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $90.10 | 2024-2025 | |
| Taiho Oncology, INC. | $87.73 | 2024 | |
| Genmab U.S., INC. | $84.38 | 2023-2024 | Epkinly |
| Servier Pharmaceuticals LLC | $84.16 | 2024-2025 | |
| Iovance Biotherapeutics, INC. | $73.43 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $68.18 | 2023-2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $62.41 | 2024-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $60.68 | 2025 | Xpovio |
| Boston Scientific Corporation | $58.12 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Deciphera Pharmaceuticals INC. | $57.62 | 2024-2025 | Qinlock, Romvimza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.85 | 2023-2025 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $33.53 | 2024 | Tavalisse, Rezlidhia |
| Emd Serono, INC. | $32.39 | 2024-2025 | |
| Gilead Sciences, INC. | $31.84 | 2023 | |
| Blueprint Medicines Corporation | $28.73 | 2024 | Ayvakit |
| Adc Therapeutics America, INC. | $28.62 | 2024 | |
| Geron Corporation | $26.50 | 2024 | Rytelo |
| Jazz Pharmaceuticals INC. | $24.36 | 2025 | |
| Recordati_rare_diseases_inc. | $24.30 | 2025 | Enjaymo |
| Celgene Corporation | $24.08 | 2024 | |
| Syndax Pharmaceuticals, INC. | $21.17 | 2025 | |
| Seagen INC. | $19.34 | 2023 | Adcetris |
| Sumitomo Pharma America, INC. | $18.73 | 2024 | Orgovyx |
| Csl Behring | $16.55 | 2024 | Afstyla, Idelvion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Wing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.